There are currently 298 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
NCT06785441
Recruiting
This protocol describes pilot testing of an educational shared decision-making intervention to help men with localized prostate cancer make decisions with their health care providers about if and when to de-escalate surveillance testing. The project is important because for many patients their cancer does not progress to the point of needed curative treatment or their health status changes such that they are no longer good candidates for treatment. For these men, de-escalating ongoing surveillan... Read More
Gender:
MALE
Ages:
65 years and above
Trial Updated:
01/31/2025
Locations: M.D. Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT06563388
Recruiting
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Gender:
ALL
Ages:
1 year and above
Trial Updated:
01/30/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
Register for Updates
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631
Recruiting
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Gender:
MALE
Ages:
45 years and above
Trial Updated:
01/29/2025
Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia +53 locations
Conditions: Prostate Cancer, Cardiovascular Disease
Register for Updates
PSMA-PET to Guide Prostatectomy
NCT05381103
Recruiting
In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
01/29/2025
Locations: Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT05435495
Recruiting
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, Los Angeles, Los Angeles, California +2 locations
Conditions: Prostate Cancer
Register for Updates
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
NCT05926102
Recruiting
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might he... Read More
Gender:
MALE
Ages:
Between 55 years and 69 years
Trial Updated:
01/29/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/28/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan +3 locations
Conditions: Prostate Cancer
Register for Updates
Hypofractionated WPPT With HDR Boost
NCT06591819
Recruiting
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
NCT02997709
Recruiting
The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET ima... Read More
Gender:
MALE
Ages:
30 years and above
Trial Updated:
01/27/2025
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer
Register for Updates
64Cu-GRIP B in Patients With Advanced Malignancies
NCT05888532
Recruiting
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Register for Updates
Ablative Therapy in the Management of Prostate Cancer
NCT03492424
Recruiting
The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Prostate Cancer
Register for Updates
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT05327465
Recruiting
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
Register for Updates